Want to join the conversation?
Biopharmaceutical company $ABBV secured FDA approval for IMBRUVICA as a first-line treatment for patients with CLL in 1Q16. In April, the company received FDA approval for Venclexta, another therapy for the treatment for CLL. Venclexta was approved for patients with relapsed/refractory CLL.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.